Lantheus Collaborates with The Prostate Cancer Clinical Trial Consortium (PCCTC) To Advance AI-Enabled Imaging Biomarkers in Prostate Cancer
27 janv. 2022 08h30 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus) announced that its subsidiary, EXINI Diagnostics AB (EXINI), has entered into a...
Lantheus Appoints Vivian Yao as Chief Human Resources Officer
01 déc. 2021 08h30 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging...
Lantheus Announces PYLARIFY AI™ is Now Available
29 nov. 2021 08h30 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging...
Lantheus Announces CMS Grants Transitional Pass-Through Payment for PYLARIFY® (piflufolastat F 18) Injection, Effective January 1, 2022
22 nov. 2021 08h30 HE
|
Lantheus Holdings, Inc.
PYLARIFY is the first and only commercially available, FDA-approved PSMA-targeted PET imaging agent for prostate cancer NORTH BILLERICA, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings,...
Lantheus Holdings Announces Presentations Featuring PYLARIFY® (Piflufolastat F 18), its PSMA-Targeted Prostate Cancer Imaging Agent, at Key Scientific Meetings
17 nov. 2021 08h30 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging...
Lantheus Holdings to Present at the 4th Annual Evercore ISI HealthCONx Conference
16 nov. 2021 16h30 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging...
Lantheus Holdings, Inc. Reports Third Quarter 2021 Financial Results
04 nov. 2021 07h00 HE
|
Lantheus Holdings, Inc.
Worldwide revenue of $102.1 million for the third quarter 2021, representing an increase of 15.3% from the prior year periodGAAP net loss of $13.4 million for the third quarter 2021, compared to GAAP...
Lantheus Holdings to Present at Upcoming Investor Conferences
28 oct. 2021 16h30 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging...
Lantheus Holdings to Host Third Quarter 2021 Earnings Conference Call and Webcast on November 4, 2021 at 8:00 a.m. Eastern Time
21 oct. 2021 08h00 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on...
Lantheus Announces Addition of PSMA PET Imaging Agent to the National Comprehensive Cancer Network® (NCCN) Guidelines for Prostate Cancer
13 sept. 2021 08h00 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging...